Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade
Open Access
- 1 January 2012
- journal article
- review article
- Published by Wiley in International Journal of Alzheimer's Disease
- Vol. 2012, 1-9
Abstract
The amyloid cascade hypothesis remains a robust model of AD neurodegeneration. However, amyloid deposits contain proteins besides Aβ, such as apolipoprotein E (apoE). Inheritance of the apoE4 allele is the strongest genetic risk factor for late-onset AD. However, there is no consensus on how different apoE isotypes contribute to AD pathogenesis. It has been hypothesized that apoE and apoE4 in particular is an amyloid catalyst or “pathological chaperone”. Alternatively it has been posited that apoE regulates Aβclearance, with apoE4 been worse at this function compared to apoE3. These views seem fundamentally opposed. The former would indicate that removing apoE will reduce AD pathology, while the latter suggests increasing brain ApoE levels may be beneficial. Here we consider the scientific basis of these different models of apoE function and suggest that these seemingly opposing views can be reconciled. The optimal therapeutic target may be to inhibit the interaction of apoE with Aβrather than altering apoE levels. Such an approach will not have detrimental effects on the many beneficial roles apoE plays in neurobiology. Furthermore, other Aβbinding proteins, including ACT and apo J can inhibit or promote Aβoligomerization/polymerization depending on conditions and might be manipulated to effect AD treatment.Keywords
Funding Information
- National Institutes of Health (AG025711, AG037942, NS073502, AG020245)
- National Institutes of Health (AG025711, AG037942, NS073502, AG020245)
- National Institutes of Health (AG025711, AG037942, NS073502, AG020245)
- National Institutes of Health (AG025711, AG037942, NS073502, AG020245)
This publication has 88 references indexed in Scilit:
- Apolipoprotein E in Alzheimer's disease and other neurological disordersThe Lancet Neurology, 2011
- Apolipoprotein E: From lipid transport to neurobiologyProgress in Lipid Research, 2011
- ATP-binding Cassette Transporter A1 Mediates the Beneficial Effects of the Liver X Receptor Agonist GW3965 on Object Recognition Memory and Amyloid Burden in Amyloid Precursor Protein/Presenilin 1 Mice*Journal of Biological Chemistry, 2010
- ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recyclingProceedings of the National Academy of Sciences, 2010
- Can Alzheimer disease be prevented by amyloid-β immunotherapy?Nature Reviews Neurology, 2010
- The Role of Apolipoprotein E in Alzheimer's DiseaseNeuron, 2009
- ApoE Promotes the Proteolytic Degradation of AβNeuron, 2008
- Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous SystemJournal of Cerebral Blood Flow & Metabolism, 2007
- Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's diseaseProceedings of the National Academy of Sciences, 2006
- Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset FamiliesScience, 1993